Dizal Pharmaceutical Co.,Ltd. (ASX: 688192) has released its preliminary financial results for the first half of 2026. The company forecasts a net loss attributable to shareholders of approximately 2.1 billion yuan, representing a year-on-year reduction in losses of about 44.35%.

The projected net loss after excluding non-recurring gains and losses is around 2.31 billion yuan, which is a decrease of roughly 44.90% compared to the same period last year.

During the reporting period, the company's two approved products, Sunvozertinib (brand name: Sunvozhe®) and Golidocitinib (brand name: Gaoruizhe®), have seen improved patient accessibility and expanding market share. This growth is attributed to their distinct clinical advantages and support from national healthcare insurance coverage, contributing to a positive trend in the company's operational performance. First-half operating revenue for 2026 is expected to reach approximately 5.22 billion yuan.

Despite the significant increase in revenue, the company continues to maintain a high level of investment in research and development as product development progresses smoothly. Consequently, a net loss for the first half of 2026 is anticipated. The company stated that its core business operations and competitive strengths remain fundamentally unchanged.